Related references
Note: Only part of the references are listed.Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
Yun-Fan Liaw et al.
GASTROENTEROLOGY (2009)
Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naive Patients Is Rare Through 5 Years of Therapy
Daniel J. Tenney et al.
HEPATOLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
ENTECAVIR MAINTAINS A HIGH GENETIC BARRIER TO HBV RESISTANCE THROUGH 6 YEARS IN NAIVE PATIENTS
D. J. Tenney et al.
JOURNAL OF HEPATOLOGY (2009)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
Stephanos J. Hadziyannis et al.
GASTROENTEROLOGY (2006)
A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B
MinDe Zeng et al.
HEPATOLOGY (2006)
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
TT Chang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
SJ Hadziyannis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Four years of lamivudine treatment in Chinese patients with chronic hepatitis B
TT Chang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B
SJ Hadziyannis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
P Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
NWY Leung et al.
HEPATOLOGY (2001)
Share Paper
